UA48939C2 - Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки - Google Patents

Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки

Info

Publication number
UA48939C2
UA48939C2 UA95125420A UA95125420A UA48939C2 UA 48939 C2 UA48939 C2 UA 48939C2 UA 95125420 A UA95125420 A UA 95125420A UA 95125420 A UA95125420 A UA 95125420A UA 48939 C2 UA48939 C2 UA 48939C2
Authority
UA
Ukraine
Prior art keywords
furanons
disubstituted
synthesis
methods
pharmaceutical composition
Prior art date
Application number
UA95125420A
Other languages
English (en)
Russian (ru)
Inventor
Ів Дюшарм
Жак І Готьє
Петпібун Презіт
Ів Леблан
Жаоін Ванг
Серж ЛЕЖЕ
Мішель Терьєн
Мишель Терьен
Original Assignee
Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Е Сі.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26767192&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA48939(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Е Сі. filed Critical Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Е Сі.
Publication of UA48939C2 publication Critical patent/UA48939C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)

Abstract

Винахід стосується дизаміщених фуранонів, які можуть застосовуватись для лікування хвороб, що опосередковуються циклооксигеназою-2. Описано також фармацевтичні композиції, до складу яких входять сполуки формули (І), призначені для лікування хвороб, що опосередковуються циклооксигеназою-2.
UA95125420A 1993-06-24 1994-06-09 Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки UA48939C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US8219693A 1993-06-24 1993-06-24
US08/179,467 US5474995A (en) 1993-06-24 1994-01-10 Phenyl heterocycles as cox-2 inhibitors
PCT/CA1994/000318 WO1995000501A2 (en) 1993-06-24 1994-06-09 Phenyl heterocycles as cyclooxygenase-2 inhibitors

Publications (1)

Publication Number Publication Date
UA48939C2 true UA48939C2 (uk) 2002-09-16

Family

ID=26767192

Family Applications (1)

Application Number Title Priority Date Filing Date
UA95125420A UA48939C2 (uk) 1993-06-24 1994-06-09 Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки

Country Status (36)

Country Link
US (5) US5474995A (uk)
EP (4) EP0980866A3 (uk)
JP (1) JP2977137B2 (uk)
KR (1) KR100215358B1 (uk)
CN (2) CN1058008C (uk)
AT (1) ATE165825T1 (uk)
AU (1) AU6967494A (uk)
BG (1) BG63161B1 (uk)
BR (1) BR9406979A (uk)
CA (5) CA2278241C (uk)
CY (1) CY2098B1 (uk)
CZ (1) CZ288175B6 (uk)
DE (1) DE69410092T2 (uk)
DK (1) DK0705254T3 (uk)
ES (1) ES2115237T3 (uk)
FI (2) FI112222B (uk)
HK (1) HK1027474A1 (uk)
HR (1) HRP940373A2 (uk)
HU (1) HU227913B1 (uk)
IL (3) IL110031A (uk)
LV (1) LV12209B (uk)
MX (1) MX9404749A (uk)
NO (1) NO307253B1 (uk)
NZ (1) NZ267386A (uk)
PL (1) PL178203B1 (uk)
RO (1) RO115354B1 (uk)
RU (1) RU2131423C1 (uk)
SA (1) SA94150039B1 (uk)
SG (1) SG52703A1 (uk)
SI (1) SI0705254T1 (uk)
SK (1) SK284114B6 (uk)
TW (1) TW326042B (uk)
UA (1) UA48939C2 (uk)
WO (1) WO1995000501A2 (uk)
YU (1) YU49053B (uk)
ZA (1) ZA944501B (uk)

Families Citing this family (465)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663180A (en) * 1983-10-29 1997-09-02 G.D. Searle & Co. Substituted cyclopentenes for the treatment of inflammation
EP0764645A1 (en) * 1993-01-15 1997-03-26 G.D. Searle & Co. Novel 3,4-diaryl furans and analogs thereof having use as anti-inflammatory agents
US6492413B2 (en) * 1993-01-15 2002-12-10 G.D. Searle & Co. 3.4-diaryl thiophenes and analogs thereof having use as antiinflammatory agents
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US6090834A (en) * 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
GB9602877D0 (en) * 1996-02-13 1996-04-10 Merck Frosst Canada Inc 3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
AU1269495A (en) * 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors
EP0772606A1 (en) * 1994-07-27 1997-05-14 G.D. SEARLE & CO. Substituted thiazoles for the treatment of inflammation
US6426360B1 (en) * 1994-07-28 2002-07-30 G D Searle & Co. 4,5-substituted imidazolyl compounds for the treatment of inflammation
US6613789B2 (en) 1994-07-28 2003-09-02 G. D. Searle & Co. Heterocyclo-substituted imidazoles for the treatment of inflammation
US5620999A (en) * 1994-07-28 1997-04-15 Weier; Richard M. Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
GB2294879A (en) * 1994-10-19 1996-05-15 Merck & Co Inc Cylcooxygenase-2 Inhibitors
DE69512930T2 (de) * 1994-10-27 2000-05-18 Merck Frosst Canada Inc Stilben-derivate verwendbar als cyclooxygenase-2 hemmer
JP2636819B2 (ja) 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
ATE232856T1 (de) * 1994-12-21 2003-03-15 Merck Frosst Canada Inc Diaryl-2(5h)-fuaranone als cox-2-inhibitoren
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
WO1996025405A1 (en) * 1995-02-13 1996-08-22 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors
US5643933A (en) * 1995-06-02 1997-07-01 G. D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
CA2223154A1 (en) 1995-06-02 1996-12-05 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6156776A (en) * 1995-06-08 2000-12-05 Yu; Dingwei Tim Diaryl substituted thiazoles useful in the treatment of fungal infections
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
EP0833622B8 (en) * 1995-06-12 2005-10-12 G.D. Searle & Co. Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
WO1996041645A1 (en) * 1995-06-12 1996-12-27 G.D. Searle & Co. Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5968974A (en) * 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
US5792778A (en) * 1995-08-10 1998-08-11 Merck & Co., Inc. 2-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5837719A (en) * 1995-08-10 1998-11-17 Merck & Co., Inc. 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use
US5786515A (en) * 1995-09-15 1998-07-28 Merck & Co., Inc. Synthesis of α-chloro or fluoro ketones
EP0853481A1 (en) * 1995-09-27 1998-07-22 Merck Frosst Canada Inc. Compositions for treating inflammation containing certain prostaglandins and a selective cyclooxygenase-2 inhibitor
US5717100A (en) * 1995-10-06 1998-02-10 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US6083949A (en) * 1995-10-06 2000-07-04 Merck & Co., Inc. Substituted imidazoles having anti-cancer and cytokine inhibitory activity
US5981576A (en) * 1995-10-13 1999-11-09 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
US6020343A (en) * 1995-10-13 2000-02-01 Merck Frosst Canada, Inc. (Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
UA57002C2 (uk) * 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
KR19990064310A (ko) * 1995-10-17 1999-07-26 윌리암스 로저 에이 시클로옥시게나제-2의 검출방법
ES2171723T3 (es) * 1995-10-30 2002-09-16 Merck Frosst Canada Inc 3,4-diaril-2-hidroxi-2,5-dihidrofuranos como profarmacos de inhibidores de cox-2.
US6222048B1 (en) * 1995-12-18 2001-04-24 Merck Frosst Canada & Co. Diaryl-2-(5H)-furanones as Cox-2 inhibitors
ES2197983T3 (es) * 1996-01-26 2004-01-16 G.D. SEARLE & CO. Imidazoles sustituidos con heterociclo para el tratamiento de la inflamacion.
ES2147973T3 (es) * 1996-02-01 2000-10-01 Merck Frosst Canada Inc Estirenos alquilatados como profarmacos de inhibidores de cox-2.
IL125441A0 (en) * 1996-02-01 1999-03-12 Merck Frosst Canada Inc Novel diphenyl stilbenes and pharmaceutical compositions thereof for treatment of cox-2 mediated diseases
US5789413A (en) * 1996-02-01 1998-08-04 Merck Frosst Canada, Inc. Alkylated styrenes as prodrugs to COX-2 inhibitors
US5733909A (en) * 1996-02-01 1998-03-31 Merck Frosst Canada, Inc. Diphenyl stilbenes as prodrugs to COX-2 inhibitors
DK0888127T3 (da) 1996-02-13 2002-04-08 Searle & Co Kombinationer med immunoundertrykkende virkninger indeholdende cyclooxygenase-2-inhibitorer og 5-lipooxygenaseinhibitortorer
WO1997029774A1 (en) 1996-02-13 1997-08-21 G.D. Searle & Co. Combinations, having immunosuppressive effects, containing a cyclooxygenase-2 inhibitor and a leukotriene a4 hydrolase inhibitor
DE69733338T2 (de) * 1996-02-13 2006-03-16 G.D. Searle & Co., Chicago Zubereitungen, enthaltend einen cyclooxygenase-2-inhibitor und einen leukotrien-b4-rezeptor-antagonisten
CN1255396C (zh) * 1996-03-18 2006-05-10 卫材株式会社 含有稠环的羧酸衍生物
ES2182035T3 (es) * 1996-03-29 2003-03-01 Merck Frosst Canada Inc Derivados del bisarilciclobuteno como inhibidores de ciclooxigenasa.
US5807873A (en) * 1996-04-04 1998-09-15 Laboratories Upsa Diarylmethylidenefuran derivatives and their uses in therapeutics
US6180651B1 (en) * 1996-04-04 2001-01-30 Bristol-Myers Squibb Diarylmethylidenefuran derivatives, processes for their preparation and their uses in therapeutics
FR2747123B1 (fr) * 1996-04-04 1998-06-26 Union Pharma Scient Appl Nouveaux derives diarylmethylidene tetrahydrofurane, leurs procedes de preparation, et leurs utilisations en therapeutique
US5908858A (en) * 1996-04-05 1999-06-01 Sankyo Company, Limited 1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
AP1009A (en) * 1996-04-12 2001-09-21 Searle & Co Substituted benzenesulfonamide derivatives as products of COX-2 inhibitors.
US5922742A (en) * 1996-04-23 1999-07-13 Merck Frosst Canada Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
EP0900201A1 (en) * 1996-04-23 1999-03-10 Merck Frosst Canada Inc. Pyridinyl-2-cyclopenten-1-ones as selective cyclooxygenase-2 inhibitors
WO1997044027A1 (en) * 1996-05-17 1997-11-27 Merck & Co., Inc. Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
CN1140267C (zh) * 1996-05-17 2004-03-03 麦克公司 治疗环加氧酶-2介导的疾病的每天一次的组合物
US6677364B2 (en) 1998-04-20 2004-01-13 G.D. Searle & Co. Substituted sulfonylphenylheterocycles as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US5883267A (en) * 1996-05-31 1999-03-16 Merck & Co., Inc. Process for making phenyl heterocycles useful as cox-2 inhibitors
HRP970289A2 (en) * 1996-05-31 1998-04-30 Merck & Co Inc Process for preparing phenyl heterocycles useful as cox-2 inhibitors
ATE294174T1 (de) * 1996-06-10 2005-05-15 Merck & Co Inc Substituierte imidazole mit cytokinin- inhibirender wirkung
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5677318A (en) * 1996-07-11 1997-10-14 Merck Frosst Canada, Inc. Diphenyl-1,2-3-thiadiazoles as anti-inflammatory agents
DK0920422T3 (da) * 1996-08-14 2003-03-17 Searle & Co Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
US6586458B1 (en) * 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
FR2753449B1 (fr) * 1996-09-13 1998-12-04 Union Pharma Scient Appl Nouveaux derives 3,4-diaryloxazolone, leurs procedes de preparation, et leurs utilisations en therapeutique
IL128568A0 (en) 1996-10-15 2000-01-31 Searle & Co Use of cyclooxygenase-2 inhibitors for the manufacture of a medicament for the treatment and prevention of neoplasia
US5776954A (en) * 1996-10-30 1998-07-07 Merck & Co., Inc. Substituted pyridyl pyrroles, compositions containing such compounds and methods of use
US5985930A (en) * 1996-11-21 1999-11-16 Pasinetti; Giulio M. Treatment of neurodegenerative conditions with nimesulide
WO1998025896A1 (en) * 1996-12-10 1998-06-18 G.D. Searle & Co. Substituted pyrrolyl compounds for the treatment of inflammation
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
WO1998041511A1 (en) * 1997-03-14 1998-09-24 Merck Frosst Canada & Co. Pyridazinones as inhibitors of cyclooxygenase-2
ES2201466T3 (es) * 1997-03-14 2004-03-16 MERCK FROSST CANADA & CO. `(metilsulfonil)fenil-2-(5h)-furanonas con enlace con oxigeno como inhibidores de cox-2`.
US6071954A (en) * 1997-03-14 2000-06-06 Merk Frosst Canada, Inc. (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
US6130334A (en) * 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
TW492959B (en) * 1997-04-18 2002-07-01 Merck & Co Inc Process for making 2-aryl-3-aryl-5-halo pyridines useful as cox-2 inhibitors
US6127545A (en) * 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6307047B1 (en) * 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
US6525053B1 (en) 1997-08-22 2003-02-25 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
EP1510519B1 (en) 1997-09-05 2006-02-15 Glaxo Group Limited Pharmaceutical compositions comprising 2,3-diarylpyrazolo[1,5-B]pyridazine derivatives
AU741754B2 (en) * 1997-09-12 2001-12-06 Merck Frosst Canada Ltd. 2-aminopyridines as inhibitors of cyclooxygenase-2
US6004950A (en) * 1997-09-12 1999-12-21 Merck Frosst Canada, Inc. 2-aminopyridines as inhibitors of cyclooxygenase-2
RS49982B (sr) 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
US6020339A (en) * 1997-10-03 2000-02-01 Merck & Co., Inc. Aryl furan derivatives as PDE IV inhibitors
US6034089A (en) * 1997-10-03 2000-03-07 Merck & Co., Inc. Aryl thiophene derivatives as PDE IV inhibitors
FR2769311B1 (fr) * 1997-10-07 1999-12-24 Union Pharma Scient Appl Nouveaux derives 3,4-diarylthiazolin-2-one ou -2-thione, leurs procedes de preparation et leurs utilisations en therapeutique
US5972986A (en) * 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
US6080876A (en) * 1997-10-29 2000-06-27 Merck & Co., Inc. Process for making phenyl heterocycles useful as COX-2 inhibitors
WO1999023087A1 (en) * 1997-10-30 1999-05-14 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors
US6133292A (en) * 1997-10-30 2000-10-17 Merck Frosst Canada & Co. Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors
AU758566B2 (en) * 1997-10-31 2003-03-27 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in maintaining the fetal ductus ateriosus during treatment and prevention of preterm labor
US6025353A (en) * 1997-11-19 2000-02-15 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
AU1703799A (en) * 1997-12-17 1999-07-05 Cornell Research Foundation Inc. Cyclooxygenase-2 inhibition
US7041694B1 (en) 1997-12-17 2006-05-09 Cornell Research Foundation, Inc. Cyclooxygenase-2 inhibition
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
NZ333399A (en) * 1997-12-24 2000-05-26 Sankyo Co Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
FR2775477B1 (fr) * 1998-02-27 2000-05-19 Union Pharma Scient Appl Nouveaux derives diarylmethylene heterocycliques, leurs procedes de preparation et leurs utilisations en therapeutique
US6136804A (en) 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
US6727238B2 (en) 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
TNSN99111A1 (fr) * 1998-06-11 2005-11-10 Pfizer Derives de sulfonylbenzene nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
JP2002523461A (ja) * 1998-08-31 2002-07-30 メルク エンド カムパニー インコーポレーテッド 神経変性疾患の治療方法
DE19842833B4 (de) 1998-09-18 2005-04-14 Merckle Gmbh 2-Arylalkylthio-imidazole, 2-Arylalkenylthio-imidazole und 2-Arylalkinylthio-imidazole als Entzündungs-Hemmstoffe und Hemmstoffe der Cytokin-Freisetzung
EP1124798A4 (en) * 1998-10-27 2002-08-28 Merck & Co Inc SYNTHESIS OF METHYLTHIOPHENYL HYDROXYKETONES
ES2234324T3 (es) * 1998-11-02 2005-06-16 MERCK & CO., INC. Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
PL348208A1 (en) 1998-11-03 2002-05-06 Glaxo Group Ltd Pyrazolopyridine derivatives as selective cox-2 inhibitors
SA99191255B1 (ar) * 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
US6155267A (en) * 1998-12-31 2000-12-05 Medtronic, Inc. Implantable medical device monitoring method and system regarding same
DE60041808D1 (de) * 1999-01-27 2009-04-30 Cornell Res Foundation Inc Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs
WO2000052008A1 (en) 1999-02-27 2000-09-08 Glaxo Group Limited Pyrazolopyridines
US6281217B2 (en) 1999-03-25 2001-08-28 Dingwei Tim Yu Class of piperazino substituted thiazoles
IL145305A0 (en) * 1999-04-14 2002-06-30 Pacific Corp 4,5-diaryl-3 (2h)-furanone derivatives as cyclooxygenase-2 inhibitors
KR20010094161A (ko) * 2000-04-04 2001-10-31 서경배 2,2-디메틸-4,5-디아릴-3(2ｈ)퓨라논의 유도체 및 이를함유하는 선택적인 시클로옥시게네이즈-2 저해제로서약제학적 조성물
CO5261541A1 (es) * 1999-05-14 2003-03-31 Pfizer Prod Inc Terapia de combinacion para el tratamiento de la migrana
CO5190664A1 (es) 1999-06-30 2002-08-29 Pfizer Prod Inc Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
US6066667A (en) * 1999-08-17 2000-05-23 Ashbrook; Charles D. Substituted furanones, compositions and antiarthritic use
AU6976400A (en) * 1999-09-08 2001-04-10 Merck Frosst Canada & Co. 1,2,3-thiadiazoles and their use as cox-2 inhibitors
AU3885901A (en) * 1999-09-21 2001-04-24 Emory University Methods and compositions for treating platelet-related disorders
PT1090915E (pt) * 1999-10-08 2009-08-03 Merial Sas Forma polimórfica b de 3-(ciclopropilmetoxi)-4-[-4-(metilsulfonil)fenil]-5,5-dimetil-5h-furan-2-ona
EP1099695A1 (en) 1999-11-09 2001-05-16 Laboratoire Theramex S.A. 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclooxygenase-2 and pharmaceutical compositions containing them
DK1104760T3 (da) 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
ES2208227T3 (es) 1999-12-03 2004-06-16 Pfizer Products Inc. Compuestos de heteroarilfenilpirazol como agentes antiinflamatorios/analgesicos.
EP1104758B1 (en) 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
ES2238324T3 (es) 1999-12-03 2005-09-01 Pfizer Products Inc. Derivados heterocicloalquilsulfonilpirazol como agentes antiinflamatorios/analgesicos.
ES2236011T3 (es) * 1999-12-08 2005-07-16 Pharmacia Corporation Formas cristalinas polimorficas de celecoxib.
AU784490B2 (en) 1999-12-08 2006-04-13 Pharmacia Corporation Cyclooxygenase-2 inhibitor compositions having rapid onset of therapeutic effect
UA74539C2 (en) 1999-12-08 2006-01-16 Pharmacia Corp Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
GB9930358D0 (en) 1999-12-22 2000-02-09 Glaxo Group Ltd Process for the preparation of chemical compounds
US6649629B2 (en) 1999-12-23 2003-11-18 Nitromed, Inc. Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
DE10001166A1 (de) 2000-01-13 2001-07-19 Merckle Gmbh Anellierte Pyrrolverbindungen, diese enthaltende pharmazeutische Mittel und deren Verwendung
DE60138535D1 (de) 2000-02-04 2009-06-10 Children S Hospital Res Founda Verwendung von lysosomal acid lipase zur behandlung von atherosklerose und ähnlichen krankheiten
KR20020071032A (ko) 2000-02-08 2002-09-11 유로-셀티크 소시에떼 아노뉨 오피오이드 효능제와 길항제를 함유하는 서방성 조성물
ES2312413T3 (es) 2000-02-08 2009-03-01 Euro-Celtique S.A. Composiciones de liberacion controlada que contienen un agonista y antagonista de opioide.
ES2166710B1 (es) * 2000-04-25 2004-10-16 J. URIACH & CIA, S.A. Nuevos compuestos heterociclicos con actividad antiinflamatoria.
AU2001255600A1 (en) * 2000-04-25 2001-11-07 Pharmacia Corporation Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes
US6686390B2 (en) * 2000-05-22 2004-02-03 Dr. Reddy's Laboratories Limited Compounds having antiinflamatory activity: process for their preparation and pharmaceutical compositions containing them
PL206268B1 (pl) 2000-06-13 2010-07-30 Wyethwyeth Kompozycja przeciwbólowa i/lub przeciwzapalna oraz jej zastosowanie
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1299123A2 (en) * 2000-07-13 2003-04-09 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
ATE366569T1 (de) * 2000-07-20 2007-08-15 Lauras As Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
US6716829B2 (en) 2000-07-27 2004-04-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
AU2001285334A1 (en) * 2000-08-29 2002-03-13 Peter Van Patten Combination for the treatment of migraine comprising a cyclooxygenase-2 inhibitor and acetylsalicylic acid
GB0021494D0 (en) * 2000-09-01 2000-10-18 Glaxo Group Ltd Chemical comkpounds
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
WO2002022124A1 (en) * 2000-09-18 2002-03-21 Merck & Co., Inc. Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist
DE10057366A1 (de) * 2000-11-18 2002-05-23 Mahle Gmbh Verfahren zur gießtechnischen Herstellung eines Kolbens mit einem gekühlten Ringträger
JP2004515550A (ja) 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
ES2245380T3 (es) 2000-12-15 2006-01-01 Glaxo Group Limited Pirazolopiridinas.
DE60122939T2 (de) 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
AUPR283801A0 (en) * 2001-02-01 2001-03-01 Australian National University, The Chemical compounds and methods
EP1363669A2 (en) * 2001-02-02 2003-11-26 Pharmacia Corporation Method of using a cyclooxygenase-2 inhibitor and sex steroids as a combination therapy for the treatment and prevention of dismenorrhea
DE10107683A1 (de) 2001-02-19 2002-08-29 Merckle Gmbh Chem Pharm Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
ES2227451T3 (es) 2001-03-08 2005-04-01 Smithkline Beecham Corporation Derivados de pirazolopiridina.
EP1372643A1 (en) 2001-03-30 2004-01-02 Smithkline Beecham Corporation Pyrazolopyridines, process for their preparation and use as therapeutic compounds
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
DE60212949T2 (de) 2001-04-10 2007-01-04 Smithkline Beecham Corp. Antivirale pyrazolopyridin verbindungen
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
DE60204452T2 (de) 2001-04-27 2005-12-15 Smithkline Beecham Corp. Pyrazolo[1,5a]Pyridinderivate
US6756498B2 (en) 2001-04-27 2004-06-29 Smithkline Beecham Corporation Process for the preparation of chemical compounds
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
EP1423114A4 (en) * 2001-05-04 2006-05-17 Merck & Co Inc METHOD AND COMPOSITIONS FOR TREATING MIGRAINE
JP4522652B2 (ja) 2001-05-11 2010-08-11 エンドー ファーマシューティカルズ， インコーポレイティド 乱用防止制御放出オピオイド投薬形態
GB0112810D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
GB0112802D0 (en) * 2001-05-25 2001-07-18 Glaxo Group Ltd Pyrimidine derivatives
US20030153801A1 (en) * 2001-05-29 2003-08-14 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease
MXPA03010991A (es) * 2001-05-31 2004-02-27 Pharmacia Corp Composicion permeable a la piel que comprende inhibidor de ciclooxigenasa-a selectivo y alcohol monohidrico.
US20060167074A1 (en) * 2001-06-19 2006-07-27 Norbert Muller Methods and compositions for the treatment of psychiatric disorders
DE10129320A1 (de) * 2001-06-19 2003-04-10 Norbert Mueller Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
HUP0400266A2 (hu) 2001-06-21 2004-08-30 Smithkline Beecham Corp. Imidazo[1,2-a]piridin-származékok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk herpeszvírus-fertőzések megelőzésére vagy kezelésére
ES2241964T3 (es) 2001-07-05 2005-11-01 Pfizer Products Inc. Heterocicloalquilsulfufonilpirazoles como agentes antiinflamatorios/abnalgesicos.
ATE419039T1 (de) 2001-07-18 2009-01-15 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
US20030157168A1 (en) 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
SI1414451T1 (sl) 2001-08-06 2009-10-31 Euro Celtique Sa Formulacije opioidnega agonista s sproščanja sposobnim in sekvestriranim antagonistom
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
GB0119477D0 (en) * 2001-08-09 2001-10-03 Glaxo Group Ltd Pyrimidine derivatives
AR038957A1 (es) 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
WO2003018575A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation 5-substituted-3(2h)-furanones useful for inhibition of farnesyl-protein transferase
US20030236308A1 (en) * 2001-09-18 2003-12-25 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
US20030114483A1 (en) * 2001-09-18 2003-06-19 Pharmacia Corporation Compositions of chromene cyclooxygenase-2 selective inhibitors and acetaminophen for treatment and prevention of inflammation, inflammation-mediated disorders and pain
BR0212778A (pt) * 2001-09-26 2004-12-07 Pharmacia Corp Composições de desintegração intra-oral organolepticamente aceitáveis
GT200200183A (es) 2001-09-28 2003-05-23 Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol
EP1432712B1 (en) 2001-10-05 2006-05-17 SmithKline Beecham Corporation Imidazo-pyridine derivatives for use in the treatment of herpes viral infection
KR100824233B1 (ko) 2001-10-10 2008-04-24 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1ｈ-나프탈렌 유도체
KR100810468B1 (ko) 2001-10-10 2008-03-07 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난1ｈ-인돌 유도체
WO2003037336A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer
ATE424388T1 (de) 2001-12-06 2009-03-15 Merck & Co Inc Mitotische kinesinhemmer
FR2833164B1 (fr) * 2001-12-07 2004-07-16 Oreal Compositions cosmetiques antisolaires a base d'un melange synergique de filtres et utilisations
ATE373000T1 (de) 2001-12-11 2007-09-15 Smithkline Beecham Corp Pyrazolopyridin-derivate als antiherpesmittel
US20040082940A1 (en) * 2002-10-22 2004-04-29 Michael Black Dermatological apparatus and method
DE10162120A1 (de) * 2001-12-12 2003-06-18 Berolina Drug Dev Ab Svedala Deuterierte substituierte Dihydrofuranone sowie diese Verbindungen enthaltende Arzneimittel
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US6667330B2 (en) 2002-01-31 2003-12-23 Galileo Pharmaceuticals, Inc. Furanone derivatives
US7985771B2 (en) * 2002-01-31 2011-07-26 Monsanto Technology Llc Furanone derivatives
KR100784341B1 (ko) 2002-04-05 2007-12-13 유로-셀띠끄 소시에떼 아노님 활성 화합물의 지속적, 불변적 및 독립적 방출용 매트릭스
MXPA04009800A (es) * 2002-04-08 2004-12-13 Glaxo Group Ltd Acido (2-((2-alcoxi)-fenil)-ciclopent-1-enil) carbociclico y heterociclico aromatico y derivados.
IL164163A0 (en) * 2002-04-09 2005-12-18 Pharmacia Corp Process for preparing a finely self-emulsifiable pharmaceutical composition
US7329401B2 (en) 2002-04-15 2008-02-12 The Regents Of The University Of California Cyclooxygenase-2 selective agents useful as imaging probes and related methods
CA2481941A1 (en) 2002-04-17 2003-10-30 The Cleveland Clinic Foundation Systemic marker for monitoring anti-inflammatory and antioxidant actions of therapeutic agents
JP2005535576A (ja) * 2002-04-22 2005-11-24 ファイザー・プロダクツ・インク シクロオキシゲナーゼ−２の選択的阻害薬としてのインドール−２−オン類
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
JP4514606B2 (ja) 2002-05-09 2010-07-28 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 心血管疾患マーカーおよび治療標的としてのｉｌ１ｒｌ−１
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
KR100804827B1 (ko) 2002-05-17 2008-02-20 씨제이제일제당 (주) 티아졸리딘-4-온 유도체, 그 제조방법 및 약제학적 조성물
US20030225054A1 (en) * 2002-06-03 2003-12-04 Jingwu Duan Combined use of tace inhibitors and COX2 inhibitors as anti-inflammatory agents
KR100478467B1 (ko) 2002-06-24 2005-03-23 씨제이 주식회사 피라졸-3-온 유도체, 그 제조방법 및 약제학적 조성물
KR100465455B1 (ko) * 2002-06-24 2005-01-13 씨제이 주식회사 2-티옥소티아졸 유도체, 그 제조방법 및 약제학적 조성물
EP1534683A4 (en) * 2002-06-27 2005-08-24 Nitromed Inc CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHOD OF USE
EP1539679A4 (en) * 2002-06-28 2007-07-04 Nitromed Inc OXIM- AND / OR HYDRAZO-CONTAINING, NITROSED AND / OR NITROSYLATED CYCLOOXIGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND USE METHODS
JP2005535657A (ja) * 2002-07-02 2005-11-24 ファルマシア・コーポレーション シクロオキシゲナーゼ−２選択阻害剤及び血栓溶解剤の血管閉塞イベントの治療又は予防への使用
KR100467668B1 (ko) * 2002-08-07 2005-01-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
AU2003258630A1 (en) * 2002-08-19 2004-03-11 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
DE10238045A1 (de) 2002-08-20 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik 2-Thio-substituierte Imidazolderivate und ihre Verwendung in der Pharmazie
UY27939A1 (es) 2002-08-21 2004-03-31 Glaxo Group Ltd Compuestos
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
CN1703200B (zh) 2002-09-20 2012-02-29 奥尔制药公司 隔离亚单元和相关组合物及方法
US8303511B2 (en) * 2002-09-26 2012-11-06 Pacesetter, Inc. Implantable pressure transducer system optimized for reduced thrombosis effect
AU2003275266A1 (en) 2002-10-03 2004-05-04 Smithkline Beecham Corporation Therapeutic compounds based on pyrazolopyridine derivatives
PL211654B1 (pl) * 2002-10-08 2012-06-29 Rinat Neuroscience Corp Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
KR100484525B1 (ko) * 2002-10-15 2005-04-20 씨제이 주식회사 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
US20040082543A1 (en) * 2002-10-29 2004-04-29 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and NMDA receptor antagonists for the treatment or prevention of neuropathic pain
JP2006507299A (ja) * 2002-10-30 2006-03-02 メルク　エンド　カムパニー　インコーポレーテッド Ａｋｔ活性の阻害薬
GB0225548D0 (en) * 2002-11-01 2002-12-11 Glaxo Group Ltd Compounds
AU2003283096A1 (en) * 2002-11-05 2004-06-07 Merck Frosst Canada And Co. Nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
KR100470075B1 (ko) 2002-11-21 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
GB0227443D0 (en) * 2002-11-25 2002-12-31 Glaxo Group Ltd Pyrimidine derivatives
KR100491317B1 (ko) 2002-11-26 2005-05-24 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
KR100470076B1 (ko) 2002-11-27 2005-02-05 씨제이 주식회사 1,2,4-트리아졸 유도체, 그 제조방법 및 약제학적 조성물
JP2006511606A (ja) 2002-12-13 2006-04-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 下部尿路症状を治療するα−２−δリガンド
PL377427A1 (pl) * 2002-12-19 2006-02-06 Pharmacia Corporation Sposoby i kompozycje do leczenia infekcji wirusem opryszczki z zastosowaniem inhibitorów selektywnych względem cyklooksygenazy-2 lub inhibitorów cyklooksygenazy-2 w połączeniu ze środkami przeciwwirusowymi
AU2003300264A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corporation Compositions of cyclooxygenase-2 selective inhibitors and selective serotonin reuptake inhibitors for the treatment or prevention of a vaso-occlusive event
SI2270048T1 (sl) * 2002-12-24 2016-01-29 Rinat Neuroscience Corp. Protitelesa proti NGF-ju in postopki uporabe le-teh
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
EP1575566B1 (en) * 2002-12-26 2012-02-22 Pozen, Inc. Multilayer dosage forms containing naproxen and triptans
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20070265606A1 (en) * 2003-02-14 2007-11-15 Reliant Technologies, Inc. Method and Apparatus for Fractional Light-based Treatment of Obstructive Sleep Apnea
AU2004213044A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
SI1608407T1 (sl) * 2003-03-20 2006-12-31 Pharmacia Corp Razprsljiva formulacija protivnetnega sredstva
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
US20040220187A1 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a sodium ion channel blocker for the treatment of pain, inflammation or inflammation mediated disorders
US20060135506A1 (en) * 2003-04-22 2006-06-22 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of pain, inflammation or inflammation mediated disorders
US20040229803A1 (en) * 2003-04-22 2004-11-18 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of pain, inflammation or inflammation mediated disorders
US20050159403A1 (en) * 2003-04-22 2005-07-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a calcium modulating agent for the treatment of central nervous system damage
US20050107387A1 (en) * 2003-05-13 2005-05-19 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a peroxisome proliferator activated receptor agonist for the treatment of ischemic mediated central nervous system disorders
WO2004105699A2 (en) * 2003-05-28 2004-12-09 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage
NZ543741A (en) 2003-05-30 2009-10-30 Ranbaxy Lab Ltd Substituted pyrrole derivatives and their use as HMG-Co inhibitors
CN1309717C (zh) * 2003-06-03 2007-04-11 李小虎 4－芳基－5h－噻吩－2－酮衍生物、其制法和用途
WO2004110492A2 (en) * 2003-06-06 2004-12-23 Glaxo Group Limited Composition comprising triptans and nsaids
EP1638573A4 (en) * 2003-06-20 2009-12-02 Merck & Co Inc USE OF SELECTIVE CYCLOOXYGENASE-2 INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS
WO2005000297A1 (en) * 2003-06-24 2005-01-06 Pharmacia Corporation Treatment of migraine accompanied by nausea
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
US20050014729A1 (en) * 2003-07-16 2005-01-20 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
WO2005009354A2 (en) * 2003-07-17 2005-02-03 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and an ikk inhibitor for the treatment of ischemic-mediated central nervous system disorders or injury
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US20050107350A1 (en) * 2003-08-22 2005-05-19 Pharmacia Corporation Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
US20050187278A1 (en) * 2003-08-28 2005-08-25 Pharmacia Corporation Treatment or prevention of vascular disorders with Cox-2 inhibitors in combination with cyclic AMP-specific phosphodiesterase inhibitors
US7282519B2 (en) * 2003-08-28 2007-10-16 Nitromed, Inc. Nitrosated and nitrosylated diuretic compounds, compositions and methods of use
EP1663184A2 (en) 2003-08-29 2006-06-07 The Brigham And Women's Hospital, Inc. Hydantoin derivatives as inhibitors of cellular necrosis
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
PL1663229T3 (pl) 2003-09-25 2010-09-30 Euro Celtique Sa Farmaceutyczne kombinacje hydrokodonu i naltreksonu
GB0323584D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
GB0323581D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Novel compounds
FR2860792B1 (fr) * 2003-10-10 2006-02-24 Sanofi Synthelabo Derives de thiophene-2-carboxamide, leur preparation et leur application en therapeutique
WO2005044227A1 (en) * 2003-11-05 2005-05-19 Glenmark Pharmaceuticals Limited Topical pharmaceutical compositions
US20050100594A1 (en) * 2003-11-12 2005-05-12 Nilendu Sen Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US7067159B2 (en) * 2003-12-05 2006-06-27 New Chapter, Inc. Methods for treating prostate cancer with herbal compositions
US7070816B2 (en) * 2003-12-05 2006-07-04 New Chapter, Inc. Methods for treating prostatic intraepithelial neoplasia with herbal compositions
EP2306192B1 (en) 2003-12-05 2015-10-14 The Cleveland Clinic Foundation Risk Markers For Cardiovascular Disease
EP1708718A1 (en) 2004-01-22 2006-10-11 Pfizer Limited Triazole derivatives which inhibit vasopressin antagonistic activity
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005081954A2 (en) * 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
WO2005081960A2 (en) * 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
BRPI0510340A (pt) * 2004-04-28 2007-10-30 Pfizer derivados de 3-heterociclil-4-feniltriazol como inibidores do receptor via da vasopressina
GB0410121D0 (en) * 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
US20080138282A1 (en) * 2004-06-03 2008-06-12 The Trustees Of Columbia University In The City Of New York Radiolabeled Arylsulfonyl Compounds and Uses Thereof
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
SI1765292T1 (en) 2004-06-12 2018-04-30 Collegium Pharmaceutical, Inc. Formulations of medicines to discourage abuse
BRPI0512832A (pt) 2004-07-01 2008-04-08 Merck & Co Inc composto ou um sal ou estereoisÈmero farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para usar um composto
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
CN101014369A (zh) * 2004-07-22 2007-08-08 法玛西亚公司 利用cox—2选择性抑制剂和ltb4受体拮抗剂的组合用于治疗炎症和疼痛的组合物
EP2494992A1 (en) 2004-08-24 2012-09-05 Merck Sharp & Dohme Corp. Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
US7622142B2 (en) * 2004-09-14 2009-11-24 New Chapter Inc. Methods for treating glioblastoma with herbal compositions
US20060064142A1 (en) * 2004-09-17 2006-03-23 Cardiac Pacemakers, Inc. Systems and methods for deriving relative physiologic measurements using an implanted sensor device
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
EP2927693A1 (en) 2004-10-06 2015-10-07 The Brigham and Women's Hospital Relevance of achieved levels of markers of systemic inflammation following treatment
EP1814535A4 (en) * 2004-11-08 2008-06-04 Nitromed Inc NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
JP2008520578A (ja) * 2004-11-15 2008-06-19 ニトロメッド インコーポレーティッド 複素環式の酸化窒素供与体基を含む利尿化合物、組成物および使用方法
TW200640865A (en) 2004-12-23 2006-12-01 Glaxo Group Ltd Compounds
EP1830886B1 (en) 2004-12-27 2016-04-13 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20080306041A1 (en) * 2005-01-21 2008-12-11 Garvey David S Cardiovascular Compounds Comprising Heterocyclic Nitric Oxide Donor Groups, Compositions and Methods of Use
KR20080016527A (ko) * 2005-01-31 2008-02-21 밀란 래보러토리즈, 인크. 하이드록시화된 네비볼롤을 함유하는 약학적 조성물
US20090042819A1 (en) * 2005-02-16 2009-02-12 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
US7521435B2 (en) * 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1858863A1 (en) * 2005-02-28 2007-11-28 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
CA2597444A1 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
WO2006110918A1 (en) * 2005-04-13 2006-10-19 Ambit Biosciences Corporation Pyrrole compounds and uses thereof
RU2445092C2 (ru) * 2005-04-28 2012-03-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Композиция, содержащая средство против деменции
AU2006244393B2 (en) * 2005-05-05 2012-06-21 Cook Biotech Incorporated Implantable materials and methods for inhibiting tissue adhesion formation
ES2382814T3 (es) 2005-05-17 2012-06-13 Merck Sharp & Dohme Ltd. Ácido cis-4-[(4-clorofenil)sulfonil]-4-(2,5-difluorofenil)ciclohexanopropanoico para el tratamiento del cáncer
WO2006123242A1 (en) * 2005-05-18 2006-11-23 Pfizer Limited 1, 2, 4 -triazole derivatives as vasopressin antagonists
EP1883614A4 (en) * 2005-05-23 2010-04-14 Nicox Sa ORGANIC NITRIC OXIDES IMPROVING SALTS FROM NON-SUBSTITUTE INFLAMMATORY COMPOUNDS AND COMPOSITIONS AND USES THEREOF
NZ563759A (en) 2005-05-31 2010-06-25 Mylan Lab Inc Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
US20090018091A1 (en) * 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
US20090054381A1 (en) * 2005-10-04 2009-02-26 Nitromed, Inc. Methods for treating respiratory disorders
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
CA2627599A1 (en) 2005-11-08 2007-05-18 Ranbaxy Laboratories Limited Process for (3r,5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino)carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
EP1954685A4 (en) * 2005-11-16 2009-11-11 Nitromed Inc FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
TW200735866A (en) 2005-11-18 2007-10-01 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
EP1971340A2 (en) * 2005-12-22 2008-09-24 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
WO2007087246A2 (en) 2006-01-24 2007-08-02 Merck & Co., Inc. Jak2 tyrosine kinase inhibition
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
HUE035884T2 (en) 2006-03-15 2018-05-28 Brigham & Womens Hospital Inc The use of gelsolin for the diagnosis and treatment of inflammatory diseases
AU2007243765A1 (en) 2006-03-29 2007-11-08 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
BRPI0710540B1 (pt) 2006-04-19 2022-04-12 Novartis Ag Compostos de benzoxazol e benzotiazol substituídos por 6-o, e composição farmacêutica
WO2007146229A2 (en) 2006-06-07 2007-12-21 Tethys Bioscience, Inc. Markers associated with arteriovascular events and methods of use thereof
DK2034975T3 (da) 2006-06-19 2012-07-23 Alpharma Pharmaceuticals Llc Farmaceutiske sammensætninger
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
WO2008039327A2 (en) 2006-09-22 2008-04-03 Merck & Co., Inc. Method of treatment using fatty acid synthesis inhibitors
US20080208179A1 (en) * 2006-10-26 2008-08-28 Reliant Technologies, Inc. Methods of increasing skin permeability by treatment with electromagnetic radiation
US8513329B2 (en) 2006-10-31 2013-08-20 Bio-Tec Environmental, Llc Chemical additives to make polymeric materials biodegradable
ES2773919T3 (es) 2006-10-31 2020-07-15 Bio Tec Env Llc Aditivos químicos para hacer biodegradables los materiales poliméricos
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA017171B1 (ru) 2006-12-22 2012-10-30 Рекордати Айерленд Лимитед КОМБИНИРОВАННАЯ ТЕРАПИЯ ЗАБОЛЕВАНИЙ НИЖНИХ МОЧЕВЫВОДЯЩИХ ПУТЕЙ С ИСПОЛЬЗОВАНИЕМ ЛИГАНДОВ αδ И НЕСТЕРОИДНЫХ ПРОТИВОВОСПАЛИТЕЛЬНЫХ ПРЕПАРАТОВ (НПВП)
KR101591656B1 (ko) 2007-01-10 2016-02-19 엠에스디 이탈리아 에스.알.엘. 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸
WO2008091530A2 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
GB0704407D0 (en) 2007-03-07 2007-04-18 Glaxo Group Ltd Compounds
CA2684308A1 (en) 2007-04-18 2008-10-30 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
EP2152700B1 (en) 2007-05-21 2013-12-11 Novartis AG Csf-1r inhibitors, compositions, and methods of use
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CA2692977A1 (en) 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
MX2010002712A (es) 2007-09-10 2010-06-09 Calcimedica Inc Compuestos que modulan calcio intracelular.
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
EP2247185B1 (en) 2008-03-03 2014-04-16 Tiger Pharmatech Tyrosine kinase inhibitors
GB2462022B (en) * 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
GB0813144D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
GB0813142D0 (en) 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
JP5782377B2 (ja) 2008-08-27 2015-09-24 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
EP2177215A1 (en) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-crystals of tramadol and NSAIDs
CN101429181A (zh) * 2008-12-18 2009-05-13 毛近隆 对羟基苯丙烯酸衍生物及其应用
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) * 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
AU2010223323B2 (en) 2009-03-10 2013-07-04 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
WO2011012622A1 (en) 2009-07-30 2011-02-03 Glaxo Group Limited Benzoxazinone derivatives for the treatment of glytl mediated disorders
WO2011023753A1 (en) 2009-08-27 2011-03-03 Glaxo Group Limited Benzoxazine derivatives as glycine transport inhibitors
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
CN102638981B (zh) 2009-10-14 2015-07-22 默沙东公司 提高p53活性的取代的哌啶和其用途
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
JP5748154B2 (ja) 2009-12-16 2015-07-15 ニヴァリス・セラピューティクス・インコーポレーテッド Ｓ−ニトロソグルタチオンレダクターゼの新規なチオフェン系阻害薬
GB201000685D0 (en) 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
AU2011210508B2 (en) 2010-02-01 2015-01-29 The Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
JP2013523240A (ja) 2010-03-31 2013-06-17 ザ・ホスピタル・フォー・シック・チルドレン 心筋梗塞後の結果を改善するための遠隔虚血コンディショニングの使用
AU2011248877B9 (en) 2010-04-27 2015-11-05 Calcimedica Inc. Compounds that modulate intracellular calcium
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
GB201007789D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel Compound
GB201007791D0 (en) 2010-05-10 2010-06-23 Glaxo Group Ltd Novel compounds
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
EP2590953B1 (en) 2010-07-09 2014-10-29 Convergence Pharmaceuticals Limited Tetrazole compounds as calcium channel blockers
CN107090456B (zh) 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
HUE044815T2 (hu) 2010-08-17 2019-11-28 Sirna Therapeutics Inc Hepatitisz B vírus (HBV) génexpressziójának RNS-interferencia közvetített gátlása, rövid interferáló nukleinsav (SINS) alkalmazásával
WO2012024650A2 (en) 2010-08-19 2012-02-23 Abbott Laboratories Anti-ngf antibodies and their use
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
US9079891B2 (en) 2010-08-27 2015-07-14 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
EP2826468A1 (en) 2010-12-22 2015-01-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
NZ612996A (en) 2010-12-23 2015-05-29 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2665729B1 (en) 2011-01-19 2015-04-01 Convergence Pharmaceuticals Limited Piperazine derivatives as cav2.2 calcium channel blockers
US20140045847A1 (en) 2011-04-21 2014-02-13 Piramal Enterprises Limited Crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
BR112013029932A2 (pt) 2011-05-20 2017-01-31 Alderbio Holdings Llc composições anti-cgrp e usos das mesmas
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
US9221809B2 (en) 2011-10-31 2015-12-29 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
WO2013165816A2 (en) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
EP2855458B1 (en) 2012-05-11 2018-08-08 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
EP2859018B1 (en) 2012-06-06 2021-09-22 Zoetis Services LLC Caninized anti-ngf antibodies and methods thereof
RU2660429C2 (ru) 2012-09-28 2018-07-06 Мерк Шарп И Доум Корп. Новые соединения, которые являются ингибиторами erk
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9655899B2 (en) 2012-11-28 2017-05-23 Merck Sharp & Dohme Corp. Compositions and methods for treating cancer
TW201429969A (zh) 2012-12-20 2014-08-01 Merck Sharp & Dohme 作爲ｈｄｍ２抑制劑之經取代咪唑吡啶
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EA201500742A1 (ru) 2013-02-05 2015-12-30 Пердью Фарма Л.П. Защищенные от нецелевого использования фармацевтические композиции
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
TWI634114B (zh) 2013-05-08 2018-09-01 永恒生物科技公司 作為激酶抑制劑之呋喃酮化合物
EP3019171B1 (en) 2013-07-11 2018-09-05 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
WO2015011189A1 (en) 2013-07-23 2015-01-29 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
US9611263B2 (en) 2013-10-08 2017-04-04 Calcimedica, Inc. Compounds that modulate intracellular calcium
US10413520B2 (en) 2014-01-29 2019-09-17 Crystalgenomics, Inc. Oral pharmacological composition including 5-{4-(amino sulfonyl)phenyl}-2,2-dimethyl-4-(3-fluorophenyl)-3(2H)-furanone having crystalline structure with excellent stability
KR101446601B1 (ko) * 2014-01-29 2014-10-07 크리스탈지노믹스(주) 5-(4-(아미노설포닐)페닐)-2,2-디메틸-4-(3-플루오로페닐)-3(2h)-퓨라논을 포함하는 약학적 조성물 및 캡슐 제형
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
GB201417500D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417499D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
GB201417497D0 (en) 2014-10-03 2014-11-19 Convergence Pharmaceuticals Novel use
RU2563876C1 (ru) * 2014-11-11 2015-09-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный университет" (СПбГУ) Способ получения 2,2-диалкил-4,5-диарилфуран-3(2н)-онов
US10040802B2 (en) 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of IRAK4 activity
EP3268367B8 (en) 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
EP3267996B1 (en) 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
EP3292213A1 (en) 2015-05-04 2018-03-14 Academisch Medisch Centrum Biomarkers for the detection of aspirin insensitivity
EP3426686A4 (en) 2016-04-15 2019-11-06 Alder Biopharmaceuticals, Inc. HUMANIZED ANTI-PACAP ANTIBODIES AND USES THEREOF
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
BR112019001127A2 (pt) 2016-07-21 2019-04-30 Unilever N.V. uso de lactama
CN109475526A (zh) 2016-07-21 2019-03-15 荷兰联合利华有限公司 用于治疗呼吸道感染的内酰胺
CN117224534A (zh) 2016-07-21 2023-12-15 联合利华知识产权控股有限公司 用于治疗皮肤损伤的内酰胺
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
CN111819197A (zh) 2018-03-12 2020-10-23 硕腾服务有限责任公司 抗ngf抗体及其方法
EP3833668A4 (en) 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3852732A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. Peg lipids and uses thereof
JP2022500543A (ja) 2018-09-19 2022-01-04 モデルナティーエックス， インコーポレイテッド 高純度ｐｅｇ脂質及びそれらの使用
CA3119728A1 (en) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Purified forms of rofecoxib, methods of manufacture and use
CN110452199B (zh) * 2019-09-03 2021-03-30 山东鲁抗舍里乐药业有限公司 一种非罗考昔的制备方法
CN110452198B (zh) * 2019-09-03 2021-03-26 山东鲁抗舍里乐药业有限公司 一种非罗考昔的制备方法
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
MX2022007535A (es) 2019-12-17 2022-09-23 Merck Sharp & Dohme Llc Inhibidores de prmt5.
CN114014824B (zh) * 2020-12-09 2023-06-13 上海科技大学 一种杂环化合物的应用
EP4306520A1 (en) * 2021-03-11 2024-01-17 Medshine Discovery Inc. Thiophene compound and application thereof
CA3209491A1 (en) 2021-03-15 2022-09-22 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
AU2022333323A1 (en) 2021-08-27 2024-02-29 H. Lundbeck A/S Treatment of cluster headache using anti-cgrp antibodies

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH423473A (de) * 1963-01-19 1966-10-31 Ciba Geigy Verfahren zur Herstellung eines photographischen Farbenbildes unter Verwendung neuer Thiophenverbindungen als Farbstoffbildner für Purpurfarbstoffe
GB1263940A (en) * 1968-08-02 1972-02-16 Innothera Lab Sa 0-phenyl-pyrroles
US3743656A (en) * 1969-05-01 1973-07-03 Wyeth John & Brother Ltd Thiophene and furan lower alkanoic acids and derivatives
GB1381860A (en) * 1971-06-03 1975-01-29 Wyeth John & Brother Ltd Tetrazole derivatives
JPS4891058A (uk) * 1972-03-10 1973-11-27
JPS4891061A (uk) * 1972-03-10 1973-11-27
US3957791A (en) * 1972-09-25 1976-05-18 Sandoz, Inc. Hydroxyalkyl-piperazino-quinoline nitrates
JPS50121261A (uk) * 1974-03-12 1975-09-23
GB1479297A (en) * 1974-07-04 1977-07-13 Beecham Group Ltd 4-substituted butan-2-ones but-3-en-2-ones butan-2-ols and but-3-en-2-ols and pharmaceutical compositions containing them
US4229207A (en) * 1975-08-15 1980-10-21 Ciba-Geigy Corporation Esters of 1,2-diphenyl-cyclohex-1-ene-4-carboxylic acid
GB2000170B (en) * 1977-06-06 1982-02-24 Eastman Kodak Co Electrophoretic migration imaging materials and process
US4318791A (en) * 1977-12-22 1982-03-09 Ciba-Geigy Corporation Use of aromatic-aliphatic ketones as photo sensitizers
US4206220A (en) * 1978-07-13 1980-06-03 Interx Research Corporation Prodrugs for the improved delivery of non-steroidal anti-inflammatory agents
US4302461A (en) * 1979-08-09 1981-11-24 E. I. Du Pont De Nemours And Company Antiinflammatory 5-substituted-2,3-diarylthiophenes
US4381311A (en) * 1980-12-29 1983-04-26 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α-(polyhalomethyl)-2-thiophenemethanols
US4427693A (en) * 1981-08-05 1984-01-24 E. I. Du Pont De Nemours And Company Antiinflammatory 4,5-diaryl-α,α-bis (polyhalomethyl)-2-thiophenemethanamines
US4820827A (en) * 1982-03-03 1989-04-11 E. I. Du Pont De Nemours And Company 2,3-diaryl-5-bromothiophene compounds of use for the treatment of inflammaton and dysmenorrhea
EP0087629B1 (en) * 1982-03-03 1986-01-15 E.I. Du Pont De Nemours And Company Antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes
US4432974A (en) * 1982-03-04 1984-02-21 E. I. Du Pont De Nemours And Company Antiinflammatory and/or analgesic 2,3-diaryl-5-silyl thiophenes
US4477463A (en) * 1982-05-10 1984-10-16 E. I. Du Pont De Nemours And Company Antiinflammatory and/or analgesic 1-alkyl-4,5-diaryl-2-fluoroalkyl-1H-pyrroles
JPS5916884A (ja) * 1982-07-19 1984-01-28 Fujisawa Pharmaceut Co Ltd 新規フラン化合物
US4543207A (en) * 1982-12-25 1985-09-24 Nippon Petrochemicals Company, Limited Electrical insulating oil and oil-filled electrical appliances
US4539332A (en) * 1983-11-14 1985-09-03 Merck & Co., Inc. 2,5-Diaryl tetrahydrofurans and analogs thereof as PAF-antagonists
US4968817A (en) * 1984-07-27 1990-11-06 National Distillers And Chemical Corporation Manufacture of gamma-crotonolactone by carbonylation of glycidol
US4652582A (en) * 1985-01-09 1987-03-24 E. I. Du Pont De Nemours And Company Antiinflammatory-2-halo-4,5-diarylpyrroles
DE3615157A1 (de) * 1986-05-05 1987-11-12 Schwabe Willmar Gmbh & Co 5-arylalkyl-4-alkoxy-2(5h)-furanone, zwischenprodukte und verfahren zu ihrer herstellung sowie ihre anwendung als therapeutische wirkstoffe
JPS6368581A (ja) * 1986-09-11 1988-03-28 Sekisui Chem Co Ltd α，β−不飽和γ−ブチロラクトンの製造方法
US4851423A (en) * 1986-12-10 1989-07-25 Schering Corporation Pharmaceutically active compounds
DE3718527A1 (de) * 1987-06-03 1988-12-15 Basf Ag Verfahren zur herstellung von 2(5h)-furanonen
DE3817808A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur herstellung von 2-substituierten pyrrolen
EP0300688A1 (en) * 1987-07-21 1989-01-25 FISONS plc Pyrrole derivatives, process for their preparation and pharmaceutical compositions containing them
DE3739882A1 (de) * 1987-11-25 1989-06-08 Bayer Ag Substituierte hydroxylamine
US4929525A (en) * 1987-12-08 1990-05-29 Fuji Electric Co., Ltd. Photoconductor for electrophotography containing azo or disazo compound
US5229386A (en) * 1989-01-05 1993-07-20 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
US5217971A (en) * 1989-01-05 1993-06-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5145860A (en) * 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5196532A (en) * 1989-02-08 1993-03-23 Basf Aktiengesellschaft Diaryl-substituted heterocyclic compounds, their preparation and drugs and cosmetics obtained therefrom
CA2012716A1 (en) * 1989-03-22 1990-09-22 Akito Tanaka Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
DE3915450A1 (de) * 1989-05-11 1990-11-15 Gerd Prof Dr Dannhardt Substituierte pyrrolverbindungen und deren anwendung in der pharmazie
AU6062590A (en) * 1989-07-07 1991-02-06 Schering Corporation Pharmaceutically active compounds
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
DE4014420A1 (de) * 1989-09-23 1991-04-04 Bayer Ag 5h-furan-2-on-derivate
US5207817A (en) * 1989-09-23 1993-05-04 Bayer Aktiengesellschaft Herbicidal 5H-furan-2-one derivatives
EP0524979A4 (en) * 1990-04-17 1993-03-10 Allergan, Inc. 2(5h)-furanones substituted in the 5 and or in the 4 position, as anti-inflammatory agents
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
JPH04279672A (ja) * 1991-03-06 1992-10-05 Mita Ind Co Ltd フェニレンジアミン系化合物およびそれを用いた電子写真感光体
JP3014162B2 (ja) * 1991-04-24 2000-02-28 積水化学工業株式会社 α，β−不飽和γ−ブチロラクトンの製造方法
IT1254558B (it) * 1992-03-26 1995-09-25 Mini Ricerca Scient Tecnolog Composti a base di 3,4-diaril-(5h)-furan-2-one ad attivita' fungicida 3
US5274072A (en) * 1992-05-04 1993-12-28 Eastman Kodak Company Polyester composition having copolymerized therein a light absorbing compound
EP0764645A1 (en) * 1993-01-15 1997-03-26 G.D. Searle & Co. Novel 3,4-diaryl furans and analogs thereof having use as anti-inflammatory agents
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
AU693110B2 (en) * 1993-08-19 1998-06-25 Warner-Lambert Company Substituted 2(5H)furanone, 2(5H)thiophenone and 2(5H)pyrrolone derivatives, their preparation and their use as endothelin antagonists
AU1269495A (en) 1994-01-10 1995-08-01 Merck Frosst Canada Inc. Phenyl heterocycles as cox-2 inhibitors

Also Published As

Publication number Publication date
HUT74070A (en) 1996-10-28
SG52703A1 (en) 1998-09-28
EP0705254A1 (en) 1996-04-10
ES2115237T3 (es) 1998-06-16
BR9406979A (pt) 1996-03-05
EP0754687A1 (en) 1997-01-22
RO115354B1 (ro) 2000-01-28
CA2176974C (en) 1999-08-24
EP0822190A1 (en) 1998-02-04
CY2098B1 (en) 2002-04-05
FI20012510A (fi) 2001-12-19
NO955256L (no) 1996-02-23
LV12209A (lv) 1999-01-20
IL123002A (en) 2001-04-30
WO1995000501A3 (en) 1995-04-13
SK150295A3 (en) 1997-01-08
WO1995000501A2 (en) 1995-01-05
HU9503319D0 (en) 1996-01-29
SK284114B6 (sk) 2004-09-08
ZA944501B (en) 1995-03-13
US5550142A (en) 1996-08-27
HRP940373A2 (en) 1996-12-31
KR100215358B1 (ko) 1999-08-16
HU227913B1 (en) 2012-05-29
DK0705254T3 (da) 1999-01-25
FI956119A0 (fi) 1995-12-19
EP0980866A3 (en) 2000-03-08
EP0980866A2 (en) 2000-02-23
CN1125944A (zh) 1996-07-03
BG100247A (bg) 1996-06-28
BG63161B1 (bg) 2001-05-31
CZ314695A3 (en) 1996-05-15
CA2176974A1 (en) 1994-12-25
US5710140A (en) 1998-01-20
CA2364039A1 (en) 1995-01-05
CA2163888A1 (en) 1995-01-05
CA2176973C (en) 2000-08-22
YU40394A (sh) 1997-08-22
CA2176973A1 (en) 1994-12-25
DE69410092T2 (de) 1998-12-17
FI114913B (fi) 2005-01-31
NZ267386A (en) 1998-02-26
FI112222B (fi) 2003-11-14
AU6967494A (en) 1995-01-17
IL123002A0 (en) 1998-08-16
HK1027474A1 (en) 2001-01-12
CA2278241A1 (en) 1994-12-25
RU2131423C1 (ru) 1999-06-10
US5536752A (en) 1996-07-16
DE69410092D1 (en) 1998-06-10
AU6197096A (en) 1996-10-31
FI956119A (fi) 1995-12-19
MX9404749A (es) 1995-01-31
CN1295065A (zh) 2001-05-16
NO955256D0 (no) 1995-12-22
CA2278241C (en) 2006-03-14
JP2977137B2 (ja) 1999-11-10
NO307253B1 (no) 2000-03-06
ATE165825T1 (de) 1998-05-15
SI0705254T1 (en) 1998-08-31
YU49053B (sh) 2003-08-29
IL110031A (en) 2000-01-31
PL312196A1 (en) 1996-04-01
LV12209B (en) 1999-03-20
JPH09500372A (ja) 1997-01-14
IL110031A0 (en) 1994-10-07
US5474995A (en) 1995-12-12
AU691119B2 (en) 1998-05-07
TW326042B (en) 1998-02-01
EP0705254B1 (en) 1998-05-06
SA94150039B1 (ar) 2005-09-19
PL178203B1 (pl) 2000-03-31
US6239173B1 (en) 2001-05-29
CZ288175B6 (en) 2001-05-16
CN1058008C (zh) 2000-11-01
CN1129576C (zh) 2003-12-03

Similar Documents

Publication Publication Date Title
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
LU91145I9 (uk)
ATE212343T1 (de) 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
DE69514813D1 (en) Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren
DE69616749D1 (de) Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe
UA39166C2 (uk) Похідні n-гідроксисечовини, що є інгібіторами ліпоксигенази у ссавців, спосіб їх одержання і спосіб інгібування ліпоксигенази у ссавців
MX9803851A (es) Compuestos macrociclicos novedosos como inhibidores de metaloproteasas.
DE69825603D1 (de) 2,3,5-trisubstituierte pyridine als inhibitoren von cyclooxygenase-2
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
PL328225A1 (en) Diphenylstilbenes as pro-medications used to produce cox-2-inhibitors
ATE293602T1 (de) 2-aminopyridine als inhibitoren von cyclooxygenase-2
ZA944317B (en) New phosphonosuccinic acid derivatives processes for the preparation thereof and pharmaceutical compositions containing them
MX9704733A (es) Monomeros de ciclohesan-1-ona 4,4-disubstituidos y compuestos relacionados.